Los Angeles, CA15 Active Studies

Brain Cancer Clinical Trials in Los Angeles, CA

Find 15 actively recruiting brain cancer clinical trials in Los Angeles, CA. Connect with local research sites and explore new treatment options.

15
Active Trials
11
Sponsors
4,632
Enrolling

Recruiting Brain Cancer Studies in Los Angeles

RecruitingLos Angeles, CANCT03970447

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple...

1,280 participants
Global Coalition for Adaptive Research
View Study Details
RecruitingLos Angeles, CANCT06556563

EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pem...

741 participants
NovoCure GmbH
View Study Details
RecruitingLos Angeles, CANCT05580562

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC...

450 participants
Chimerix
View Study Details
RecruitingLos Angeles, CANCT05566795

DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)

This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in ...

400 participants
Day One Biopharmaceuticals, Inc.
View Study Details
RecruitingLos Angeles, CANCT05009992

Combination Therapy for the Treatment of Diffuse Midline Gliomas

This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years o...

360 participants
University of California, San Francisco
View Study Details
RecruitingLos Angeles, CANCT05438212

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain ...

236 participants
NRG Oncology
View Study Details
RecruitingLos Angeles, CANCT04166409

A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma

This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated lo...

220 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CANCT04804644

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the...

200 participants
NRG Oncology
View Study Details
RecruitingLos Angeles, CANCT06325683

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with g...

184 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CANCT05708352

A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Di...

170 participants
Cedars-Sinai Medical Center
View Study Details
RecruitingLos Angeles, CANCT05099003

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse...

132 participants
National Cancer Institute (NCI)
View Study Details
RecruitingLos Angeles, CANCT03382977

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM)....

98 participants
VBI Vaccines Inc.
View Study Details
RecruitingLos Angeles, CANCT06504381

DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma

This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patie...

70 participants
University of California, San Francisco
View Study Details
RecruitingLos Angeles, CANCT02704858

Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

This multi-site, Phase 1/2a clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of pa...

49 participants
Neonc Technologies, Inc.
View Study Details
RecruitingLos Angeles, CANCT06478212

Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma

The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. Th...

42 participants
Institut de Recherches Internationales Servier
View Study Details

About Brain Cancer Clinical Trials in Los Angeles

Brain cancer includes tumors that originate in the brain (primary) or spread from other areas (metastatic). Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Treatment typically combines surgery, radiation, and chemotherapy, with immunotherapy trials underway.

There are currently 15 brain cancer clinical trials recruiting participants in Los Angeles, CA. These studies are seeking a combined 4,632 participants. Research is being sponsored by Global Coalition for Adaptive Research, NovoCure GmbH, Chimerix and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Brain Cancer Clinical Trials in Los Angeles — FAQ

Are there brain cancer clinical trials in Los Angeles?

Yes, there are 15 brain cancer clinical trials currently recruiting in Los Angeles, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Los Angeles?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Los Angeles research site will contact you about next steps.

Are clinical trials in Los Angeles free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Los Angeles studies also compensate for your time and travel.

What brain cancer treatments are being tested?

The 15 active trials in Los Angeles are testing new therapies including novel drugs, biologics, and treatment approaches for brain cancer.

Data updated March 2, 2026 from ClinicalTrials.gov